The introduction of Biogen Idec Inc.’s multiple sclerosis pill, Tecfidera, outstripped the initial sales of competing drugs from Novartis AG and Sanofi, suggesting the treatment may beat estimates for the year.
Biogen Idec Inc., the fourth- largest U.S. biotechnology company by market value, won a U.S. patent that may guard its experimental multiple sclerosis pill from generic competition for eight more years than anticipated.
Sanofi won backing from a European advisory panel for its first multiple sclerosis therapy, the tablet Aubagio, a step forward in the French drugmaker’s plan to grab a slice of the $14 billion MS business.
Biogen Idec Inc.’s longer-lasting injectable multiple sclerosis drug, peginterferon beta-1a, helped reduce the risk of relapse by 36 percent when given every two weeks, meeting the goals of a late-stage study.
Novartis AG’s Gilenya multiple sclerosis pill lost market share for the first time in January, following the deaths of some patients soon after taking the first pill available for the disease in the U.S.